<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">surgonco</journal-id><journal-title-group><journal-title xml:lang="ru">Креативная хирургия и онкология</journal-title><trans-title-group xml:lang="en"><trans-title>Creative surgery and oncology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2076-3093</issn><issn pub-type="epub">2307-0501</issn><publisher><publisher-name>Башкирский государственный медицинский университет</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.24060/2076-3093-2021-11-2-166-173</article-id><article-id custom-type="elpub" pub-id-type="custom">surgonco-587</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОБЗОР ЛИТЕРАТУРЫ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>REVIEWS</subject></subj-group></article-categories><title-group><article-title>Геномные и протеомные маркеры и перспективы их использования при раке шейки матки</article-title><trans-title-group xml:lang="en"><trans-title>Genomic and Proteomic Markers of Cervical Cancer: a Prospective Outlook</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5542-9531</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Минязева</surname><given-names>Р. К.</given-names></name><name name-style="western" xml:lang="en"><surname>Minyazeva</surname><given-names>R. K.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Минязева Раушания Каримовна — кафедра акушерства и гинекологии № 1</p><p>Россия, Республика Башкортостан, Уфа</p></bio><bio xml:lang="en"><p>Raushaniya K. Minyazeva — Department of Obstetrics and Gynaecology No. 1,</p><p>Ufa, Russian Federation</p></bio><email xlink:type="simple">Dr.gubaydullina@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1641-9952</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Батталова</surname><given-names>Г. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Battalova</surname><given-names>G. Y.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Батталова Гюзель Юрьевна — д.м.н., профессор, кафедра акушерства и гинекологии № 1, радиологическое отделение № 3</p><p>Россия, Республика Башкортостан, Уфа</p></bio><bio xml:lang="en"><p>Gyuzel Y. Battalova — Dr. Sci. (Med.), Prof., Department of Obstetrics and Gynaecology No. 1, Radiology Unit No. 3</p><p>Ufa, Russian Federation</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сахаутдинова</surname><given-names>И. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Sakhautdinova</surname><given-names>I. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Сахаутдинова Индира Венеровна — д.м.н., кафедра акушерства и гинекологии № 1</p><p>Россия, Республика Башкортостан, Уфа</p></bio><bio xml:lang="en"><p>Indira V. Sakhautdinova — Dr. Sci. (Med.), Department of Obstetrics and Gynaecology No. 1</p><p>Ufa, Russian Federation</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9499-5632</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гилязова</surname><given-names>И. Р.</given-names></name><name name-style="western" xml:lang="en"><surname>Gilyazova</surname><given-names>I. R.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Гилязова Ирина Ришатовна — к.б.н., кафедра медицинской генетики и фундаментальной медицины, лаборатория молекулярной генетики человека</p><p>Россия, Республика Башкортостан, Уфа</p></bio><bio xml:lang="en"><p>Irina R. Gilyazova — Cand. Sci. (Biol.), Department of Medical Genetics and Fundamental Medicine, Laboratory of Human Molecular Genetics</p><p>Ufa, Russian Federation</p></bio><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Башкирский государственный медицинский университет</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Bashkir State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Башкирский государственный медицинский университет; Республиканский клинический онкологический диспансер</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Bashkir State Medical University; Republican Clinical Oncological Dispensary</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Башкирский государственный медицинский университет; Институт биохимии и генетики Уфимского федерального научного центра РАН</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Bashkir State Medical University; Institute of Biochemistry and Genetics of Ufa Federal Research Centre of the Russian Academy of Sciences</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2021</year></pub-date><pub-date pub-type="epub"><day>22</day><month>05</month><year>2021</year></pub-date><volume>11</volume><issue>2</issue><fpage>166</fpage><lpage>173</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Минязева Р.К., Батталова Г.Ю., Сахаутдинова И.В., Гилязова И.Р., 2021</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="ru">Минязева Р.К., Батталова Г.Ю., Сахаутдинова И.В., Гилязова И.Р.</copyright-holder><copyright-holder xml:lang="en">Minyazeva R.K., Battalova G.Y., Sakhautdinova I.V., Gilyazova I.R.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.surgonco.ru/jour/article/view/587">https://www.surgonco.ru/jour/article/view/587</self-uri><abstract><p>Гинекологические злокачественные новообразования представляют собой серьезную проблему для здоровья женщин всего мира. Среди этих проблем, в частности, рак шейки матки (РШМ), который является одним из наиболее часто встречаемых злокачественных новообразований репродуктивной сферы женского населения, вызванным неконтролируемым делением клеток и приводящим к поражению тканей шейки матки у женщин. С появлением новых технологий исследователи направляют свои усилия на поиск и разработку новых маркеров для ранней диагностики, а также оценки и мониторинга терапевтических методов лечения. Несмотря на многочисленные попытки исследователей раскрыть молекулярные механизмы развития РШМ, патогенез заболевания во многом остается неясным. Изучение потенциальных предикторов рака шейки матки имеет решающее значение для разработки эффективного лечения этого заболевания. В настоящее время для решения этой задачи применяются подходы системной биологии, основанные на высокопроизводительных технологиях. По- казано, что по сравнению с традиционными методами технология системной биологии предоставляет большой объем информации о прогностических биомаркерах и терапевтических целях для рака шейки матки. Поиск новых молекулярных маркеров с высокой чувствительностью и специфичностью продолжается с использованием технологии системной биологии. Такой подход поможет в совершенствовании ранней диагностики и в повышении эффективности лечения больных с уменьшением количества рецидивов. В настоящем обзоре представлены доступные на сегодняшний день, а также разрабатываемые биомаркеры для диагностики и прогноза рака шейки матки, основанные на клеточных и молекулярных методах.</p></abstract><trans-abstract xml:lang="en"><p>Gynaecological malignancy is a major challenge in women’s health worldwide. Cervical cancer (CC) is a particularly common type affecting the female reproductive system through an uncontrolled cell propagation causing cervical tissue injury in women. The advent of new technologies empowers research into the discovery and development of novel markers for early diagnosis, as well as therapy evaluation and monitoring. Despite manifold attempts to unravel the molecular mechanisms of CC, its pathogenesis remains largely unclear. The study of putative CC predictors is key to the invention of effective alleviating treatments. Systems biology enabled with high-throughput methods currently provides routes to tackle this problem. Unlike a traditional approach, it generates a wealth of data on prognostic biomarkers and therapeutic targets in cervical cancer, fuelling the search for novel high-sensitive and specific molecular markers. This approach will help improve the early diagnosis and treatment efficacy at a lower relapse rate. This review presents the currently on-stage and emerging biomarkers in cellular and molecular research into cervical cancer detection and prognosis.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>рак шейки матки</kwd><kwd>биомаркеры новообразований</kwd><kwd>прогноз</kwd><kwd>опухолевые антигены</kwd><kwd>предраковые состояния</kwd><kwd>дисплазия шейки матки</kwd><kwd>папилломавирус</kwd></kwd-group><kwd-group xml:lang="en"><kwd>cervical cancer</kwd><kwd>tumour biomarkers</kwd><kwd>prognosis</kwd><kwd>tumour antigens</kwd><kwd>precancerous conditions</kwd><kwd>cervical dysplasia</kwd><kwd>papillomavirus</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Hu Z., Ma D. The precision prevention and therapy of HPV-related cervical cancer new concepts and clinical implications. Cancer Medicine 2018;7(10):5217–36. DOI: 10.1002/cam4.1501</mixed-citation><mixed-citation xml:lang="en">Hu Z., Ma D. The precision prevention and therapy of HPV-related cervical cancer new concepts and clinical implications. Cancer Medicine 2018;7(10):5217–36. DOI: 10.1002/cam4.1501</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Christensen J.T., Grønhøj C., Zamani M., Brask J., Kjær E., Lajer H., et al. Association between oropharyngeal cancers with known HPV and p16 status and cervical intraepithelial neoplasia: a Danish population-based study. Acta Oncologica. 2018;58(3):267–72. DOI: 10.1080/0284186X.2018.1546059</mixed-citation><mixed-citation xml:lang="en">Christensen J.T., Grønhøj C., Zamani M., Brask J., Kjær E., Lajer H., et al. Association between oropharyngeal cancers with known HPV and p16 status and cervical intraepithelial neoplasia: a Danish population-based study. Acta Oncologica. 2018;58(3):267–72. DOI: 10.1080/0284186X.2018.1546059</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Каприн А.Д., Старинский В.В., Шахзадова А.О. (ред.). Состояние онкологической помощи населению России в 2019 году. М.: МНИОИ им. Герцена — филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2020.</mixed-citation><mixed-citation xml:lang="en">Kaprin A.D., Starinsky V.V., Shakhzadova A.O. (editors). State of cancer care for population in Russia in 2019. Moscow: National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, 2020 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Global strategy to accelerate the elimination of cervical cancer as a public health problem. WHO; 2020. 52 p.</mixed-citation><mixed-citation xml:lang="en">Global strategy to accelerate the elimination of cervical cancer as a public health problem. WHO; 2020. 52 p.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Дмитриади Т.А., Кит О.И., Бурцев Д.В. Скрининг рака шейки матки. Мировой опыт. Ситуация в России. Известия высших учебных заведений. Северо-Кавказский регион. Серия: естественные на- уки. 2017;4-2(196-2):26–32. DOI: 10.23683/0321-3005-2017-4-2-26-32</mixed-citation><mixed-citation xml:lang="en">Dmitriadi T.A., Kit O.I., Burtsev D.V. Screening of cervical cancer. World experience. Situation in Russia. Bulletin of higher education institutes. North Caucasus region. Natural sciences. 2017;4-2(196-2):26–32 (In Russ). DOI: 10.23683/0321-3005-2017-4-2-26-32</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Valenti G., Vitale S.G., Tropea A., Biondi A., Laganà A.S. Tumor markers of uterine cervical cancer: a new scenario to guide surgical practice? Updates Surg. 2017;69:441–9. DOI: 10.1007/s13304-017-0491-3</mixed-citation><mixed-citation xml:lang="en">Valenti G., Vitale S.G., Tropea A., Biondi A., Laganà A.S. Tumor markers of uterine cervical cancer: a new scenario to guide surgical practice? Updates Surg. 2017;69:441–9. DOI: 10.1007/s13304-017-0491-3</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Lees B., Erickson B.K., Huh W.K. Cervical cancer screening: evidence behind the guidelines. Obstet Gynecol. 2016;214(4):438–43. DOI: 10.1016/j.ajog.2015.10.147</mixed-citation><mixed-citation xml:lang="en">Lees B., Erickson B.K., Huh W.K. Cervical cancer screening: evidence behind the guidelines. Obstet Gynecol. 2016;214(4):438–43. DOI: 10.1016/j.ajog.2015.10.147</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Shah U.J., Nasiruddin M., Dar S.A., Khan K.A., Akhter M.R., Singh N., et al. Emerging biomarkers and clinical significance of HPV genotyping in prevention and management of cervical cancer. Microb Pathog. 2020;143:104131. DOI: 10.1016/j.micpath.2020.104131</mixed-citation><mixed-citation xml:lang="en">Shah U.J., Nasiruddin M., Dar S.A., Khan K.A., Akhter M.R., Singh N., et al. Emerging biomarkers and clinical significance of HPV genotyping in prevention and management of cervical cancer. Microb Pathog. 2020;143:104131. DOI: 10.1016/j.micpath.2020.104131</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Novikova T. Optical techniques for cervical neoplasia detection. Beilstein J Nanotechnol. 2017;8:1844–62. DOI: 10.3762/bjnano.8.186</mixed-citation><mixed-citation xml:lang="en">Novikova T. Optical techniques for cervical neoplasia detection. Beilstein J Nanotechnol. 2017;8:1844–62. DOI: 10.3762/bjnano.8.186</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Malati T. Tumour markers: An overview. Indian J Clin Biochem. 2007;22(2):17–31. DOI: 10.1007/BF02913308</mixed-citation><mixed-citation xml:lang="en">Malati T. Tumour markers: An overview. Indian J Clin Biochem. 2007;22(2):17–31. DOI: 10.1007/BF02913308</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Bahrami A., Hasanzadeh M., Shahidsales S., Farazestanian M., Hassanian S.M., Moetamani Ahmadi M., et al. Genetic susceptibility in cervical cancer: from bench to bedside. J Cell Physiol. 2018;233(3):1929–39. DOI: 10.1002/jcp.26019</mixed-citation><mixed-citation xml:lang="en">Bahrami A., Hasanzadeh M., Shahidsales S., Farazestanian M., Hassanian S.M., Moetamani Ahmadi M., et al. Genetic susceptibility in cervical cancer: from bench to bedside. J Cell Physiol. 2018;233(3):1929–39. DOI: 10.1002/jcp.26019</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Van Ostade X., Dom M., Tjalma W., Van Raemdonck G. Candidate biomarkers in the cervical vaginal fluid for the (self-)diagnosis of cervical precancer. Arch Gynecol Obstet. 2018;297(2):295–311. DOI: 10.1007/s00404-017-4587-2</mixed-citation><mixed-citation xml:lang="en">Van Ostade X., Dom M., Tjalma W., Van Raemdonck G. Candidate biomarkers in the cervical vaginal fluid for the (self-)diagnosis of cervical precancer. Arch Gynecol Obstet. 2018;297(2):295–311. DOI: 10.1007/s00404-017-4587-2</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Hu Z., Ma D. The precision prevention and therapy of HPV-related cervical cancer: new concepts and clinical implications. Cancer Med. 2018;7(10):5217–36. DOI: 10.1002/cam4.1501</mixed-citation><mixed-citation xml:lang="en">Hu Z., Ma D. The precision prevention and therapy of HPV-related cervical cancer: new concepts and clinical implications. Cancer Med. 2018;7(10):5217–36. DOI: 10.1002/cam4.1501</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Walker J.L., Wang S.S., Schiffman M., Solomon D. Predicting absolute risk of CIN3 during post-colposcopic follow-up: results from the ASCUS-LSIL Triage Study (ALTS). Am J Obstet Gynecol. 2006;195(2):341–8. DOI: 10.1016/j.ajog.2006.02.047</mixed-citation><mixed-citation xml:lang="en">Walker J.L., Wang S.S., Schiffman M., Solomon D. Predicting absolute risk of CIN3 during post-colposcopic follow-up: results from the ASCUS-LSIL Triage Study (ALTS). Am J Obstet Gynecol. 2006;195(2):341–8. DOI: 10.1016/j.ajog.2006.02.047</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Castle P.E., Solomon D., Schiffman M., Wheeler C.M. Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities. J Natl Cancer Inst. 2005;97(14):1066–71. DOI: 10.1093/jnci/dji186</mixed-citation><mixed-citation xml:lang="en">Castle P.E., Solomon D., Schiffman M., Wheeler C.M. Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities. J Natl Cancer Inst. 2005;97(14):1066–71. DOI: 10.1093/jnci/dji186</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Campitelli M., Jeannot E., Peter M., Lappartient E., Saada S., de la Rochefordière A., et al. Human papillomavirus mutational insertion: specific marker of circulating tumor DNA in cervical cancer patients. PLoS One. 2012;7(8):e43393. DOI: 10.1371/journal.pone.0043393</mixed-citation><mixed-citation xml:lang="en">Campitelli M., Jeannot E., Peter M., Lappartient E., Saada S., de la Rochefordière A., et al. Human papillomavirus mutational insertion: specific marker of circulating tumor DNA in cervical cancer patients. PLoS One. 2012;7(8):e43393. DOI: 10.1371/journal.pone.0043393</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Kontostathi G., Zoidakis J., Anagnou N.P., Pappa K.I., Vlahou A., Makridakis M. Proteomics approaches in cervical cancer: focus on the discovery of biomarkers for diagnosis and drug treatment monitoring. Expert Rev Proteomics. 2016;13(8):731–45. DOI: 10.1080/14789450.2016.1210514</mixed-citation><mixed-citation xml:lang="en">Kontostathi G., Zoidakis J., Anagnou N.P., Pappa K.I., Vlahou A., Makridakis M. Proteomics approaches in cervical cancer: focus on the discovery of biomarkers for diagnosis and drug treatment monitoring. Expert Rev Proteomics. 2016;13(8):731–45. DOI: 10.1080/14789450.2016.1210514</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Matsuo K., Machida H., Mandelbaum R.S., Konishi I., Mikami M. Validation of the 2018 FIGO cervical cancer staging system. Gynecol Oncol. 2019;152:87–93. DOI: 10.1016/j.ygyno.2018.10.026</mixed-citation><mixed-citation xml:lang="en">Matsuo K., Machida H., Mandelbaum R.S., Konishi I., Mikami M. Validation of the 2018 FIGO cervical cancer staging system. Gynecol Oncol. 2019;152:87–93. DOI: 10.1016/j.ygyno.2018.10.026</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Choi K.H., Lee S.W., Yu M., Jeong S., Lee J.W., Lee J.H. Significance of elevated SCC-Ag level on tumor recurrence and patient survival in patients with squamous-cell carcinoma of uterine cervix following definitive chemoradiotherapy: a multi-institutional analysis. J Gynecol Oncol. 2019;30(1):e1. DOI: 10.3802/jgo.2019.30.e1</mixed-citation><mixed-citation xml:lang="en">Choi K.H., Lee S.W., Yu M., Jeong S., Lee J.W., Lee J.H. Significance of elevated SCC-Ag level on tumor recurrence and patient survival in patients with squamous-cell carcinoma of uterine cervix following definitive chemoradiotherapy: a multi-institutional analysis. J Gynecol Oncol. 2019;30(1):e1. DOI: 10.3802/jgo.2019.30.e1</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Xu F., Li Y., Fan L., Ma J., Yu L., Yi H., et al. Preoperative SCC-Ag and thrombocytosis as predictive markers for pelvic lymphatic metastasis of squamous cervical cancer in early FIGO stage. J Cancer. 2018;9:1660–66. DOI: 10.7150/jca.24049</mixed-citation><mixed-citation xml:lang="en">Xu F., Li Y., Fan L., Ma J., Yu L., Yi H., et al. Preoperative SCC-Ag and thrombocytosis as predictive markers for pelvic lymphatic metastasis of squamous cervical cancer in early FIGO stage. J Cancer. 2018;9:1660–66. DOI: 10.7150/jca.24049</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Yang H., Hu H., Gou Y., Hu Y., Li H., Zhao H., et al. Combined detection of Twist1, Snail1 and squamous cell carcinoma antigen for the prognostic evaluation of invasion and metastasis in cervical squamous cell carcinoma. Int J Clin Oncol. 2018;23:321–8. DOI: 10.1007/s10147-017-1210-2</mixed-citation><mixed-citation xml:lang="en">Yang H., Hu H., Gou Y., Hu Y., Li H., Zhao H., et al. Combined detection of Twist1, Snail1 and squamous cell carcinoma antigen for the prognostic evaluation of invasion and metastasis in cervical squamous cell carcinoma. Int J Clin Oncol. 2018;23:321–8. DOI: 10.1007/s10147-017-1210-2</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Xu D., Wang D., Wang S., Tian Y., Long Z., Ren X. Correlation between squamous cell carcinoma antigen level and the Clinicopathological features of early-stage cervical squamous cell carcinoma and the predictive value of squamous cell carcinoma antigen combined with computed tomography scan for lymph node metastasis. Int J Gynecol Cancer. 2017;27:1935–42. DOI: 10.1097/IGC.0000000000001112</mixed-citation><mixed-citation xml:lang="en">Xu D., Wang D., Wang S., Tian Y., Long Z., Ren X. Correlation between squamous cell carcinoma antigen level and the Clinicopathological features of early-stage cervical squamous cell carcinoma and the predictive value of squamous cell carcinoma antigen combined with computed tomography scan for lymph node metastasis. Int J Gynecol Cancer. 2017;27:1935–42. DOI: 10.1097/IGC.0000000000001112</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Markovina S., Wang S., Henke L.E., Luke C.J., Pak S.C., DeWees T., et al. Serum squamous cell carcinoma antigen as an early indicator of response during therapy of cervical cancer. Br J Cancer. 2018;118:72–8. DOI: 10.1038/bjc.2017.390</mixed-citation><mixed-citation xml:lang="en">Markovina S., Wang S., Henke L.E., Luke C.J., Pak S.C., DeWees T., et al. Serum squamous cell carcinoma antigen as an early indicator of response during therapy of cervical cancer. Br J Cancer. 2018;118:72–8. DOI: 10.1038/bjc.2017.390</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Kubik S., Moszynska-Zielinska M., Fijuth J., Tomalczyk A., Jesionek- Kupnicka D., Ura L., et al. Assessment of the relationship between serum squamous cell carcinoma antigen (SCC-Ag) concentration in patients with locally advanced squamous cell carcinoma of the uterine cervix and the risk of relapse. Prz Menopauzalny. 2019;18(1):23–6. DOI: 10.5114/pm.2019.84153</mixed-citation><mixed-citation xml:lang="en">Kubik S., Moszynska-Zielinska M., Fijuth J., Tomalczyk A., Jesionek- Kupnicka D., Ura L., et al. Assessment of the relationship between serum squamous cell carcinoma antigen (SCC-Ag) concentration in patients with locally advanced squamous cell carcinoma of the uterine cervix and the risk of relapse. Prz Menopauzalny. 2019;18(1):23–6. DOI: 10.5114/pm.2019.84153</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Huang E.Y., Huang Y.J., Chanchien C.C., Lin H., Wang C.J., Sun L.M., et al. Pretreatment carcinoembryonic antigen level is a risk factor for Para-aortic lymph node recurrence in addition to squamous cell carcinoma antigen following definitive concurrent chemoradiotherapy for squamous cell carcinoma of the uterine cervix. Radiat Oncol. 2012;7:13. DOI: 10.1186/1748-717X-7-13</mixed-citation><mixed-citation xml:lang="en">Huang E.Y., Huang Y.J., Chanchien C.C., Lin H., Wang C.J., Sun L.M., et al. Pretreatment carcinoembryonic antigen level is a risk factor for Para-aortic lymph node recurrence in addition to squamous cell carcinoma antigen following definitive concurrent chemoradiotherapy for squamous cell carcinoma of the uterine cervix. Radiat Oncol. 2012;7:13. DOI: 10.1186/1748-717X-7-13</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Mabuchi S., Isohashi F., Yokoi T., Takemura M., Yoshino K., Shiki Y., et al. A phase II study of postoperative concurrent carboplatin and paclitaxel combined with intensity-modulated pelvic radiotherapy followed by consolidation chemotherapy in surgically treated cervical cancer patients with positive pelvic lymph nodes. Gynecol Oncol. 2016;141:240–6. DOI: 10.1016/j.ygyno.2016.02.011</mixed-citation><mixed-citation xml:lang="en">Mabuchi S., Isohashi F., Yokoi T., Takemura M., Yoshino K., Shiki Y., et al. A phase II study of postoperative concurrent carboplatin and paclitaxel combined with intensity-modulated pelvic radiotherapy followed by consolidation chemotherapy in surgically treated cervical cancer patients with positive pelvic lymph nodes. Gynecol Oncol. 2016;141:240–6. DOI: 10.1016/j.ygyno.2016.02.011</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Wang W., Liu X., Meng Q., Zhang F., Hu K. Prophylactic extended-field irradiation for patients with cervical Cancer treated with concurrent Chemoradiotherapy: a propensity-score matching analysis. Int J Gynecol Cancer. 2018;28:1584–91. DOI: 10.1097/IGC.0000000000001344</mixed-citation><mixed-citation xml:lang="en">Wang W., Liu X., Meng Q., Zhang F., Hu K. Prophylactic extendedfield irradiation for patients with cervical Cancer treated with concurrent Chemoradiotherapy: a propensity-score matching analysis. Int J Gynecol Cancer. 2018;28:1584–91. DOI: 10.1097/IGC.0000000000001344</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Takeda M., Sakuragi N., Okamoto K., Todo Y., Minobe S.I., Nomura E., et al. Preoperative serum SCC, CA125 and CA19-9 levels and lymph node status in squamous cell carcinoma of the uterine cervix. Acta Obstet Gynecol Scand. 2002;81(5):451–7. DOI: 10.1034/j.1600-0412.2002.810513.x</mixed-citation><mixed-citation xml:lang="en">Takeda M., Sakuragi N., Okamoto K., Todo Y., Minobe S.I., Nomura E., et al. Preoperative serum SCC, CA125 and CA19-9 levels and lymph node status in squamous cell carcinoma of the uterine cervix. Acta Obstet Gynecol Scand. 2002;81(5):451–7. DOI: 10.1034/j.1600-0412.2002.810513.x</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Fu J., Wang W., Wang Y., Liu C., Wang P. The role of squamous cell carcinoma antigen (SCC Ag) in outcome prediction after concurrent chemoradiotherapy and treatment decisions for patients with cervical cancer. Radiat Oncol. 2019;14(1):146. DOI: 10.1186/s13014-019-1355-4</mixed-citation><mixed-citation xml:lang="en">Fu J., Wang W., Wang Y., Liu C., Wang P. The role of squamous cell carcinoma antigen (SCC Ag) in outcome prediction after concurrent chemoradiotherapy and treatment decisions for patients with cervical cancer. Radiat Oncol. 2019;14(1):146. DOI: 10.1186/s13014-019-1355-4</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Farzaneh F., Shahghassempour S., Noshine B., Arab M., Yaseri M., Rafizadeh M., et al. Application of tumor markers SCC-Ag, CEA, and TPA in patients with cervical precancerous lesions. Asian Pac J Cancer Prev. 2014;15(9):3911–4. DOI: 10.7314/apjcp.2014.15.9.3911</mixed-citation><mixed-citation xml:lang="en">Farzaneh F., Shahghassempour S., Noshine B., Arab M., Yaseri M., Rafizadeh M., et al. Application of tumor markers SCC-Ag, CEA, and TPA in patients with cervical precancerous lesions. Asian Pac J Cancer Prev. 2014;15(9):3911–4. DOI: 10.7314/apjcp.2014.15.9.3911</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Kotowicz B., Fuksiewicz M., Jonska-Gmyrek J., Bidzinski M., Kowalska M. The assessment of the prognostic value of tumor markers and cytokines as SCCAg, CYFRA 21.1, IL-6, VEGF and sTNF receptors in patients with squamous cell cervical cancer, particularly with early stage of the disease. Tumour Biol. 2016;37(1):1271–8. DOI: 10.1007/s13277-015-3914-0</mixed-citation><mixed-citation xml:lang="en">Kotowicz B., Fuksiewicz M., Jonska-Gmyrek J., Bidzinski M., Kowalska M. The assessment of the prognostic value of tumor markers and cytokines as SCCAg, CYFRA 21.1, IL-6, VEGF and sTNF receptors in patients with squamous cell cervical cancer, particularly with early stage of the disease. Tumour Biol. 2016;37(1):1271–8. DOI: 10.1007/s13277-015-3914-0</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Konishi T., Shimada Y., Hsu M., Tufts L., Jimenez-Rodriguez R., Cercek A., et al. Association of preoperative and postoperative serum carcinoembryonic antigen and colon cancer outcome. JAMA Oncol. 2018;4(3):309–15. DOI: 10.1001/jamaoncol.2017.4420</mixed-citation><mixed-citation xml:lang="en">Konishi T., Shimada Y., Hsu M., Tufts L., Jimenez-Rodriguez R., Cercek A., et al. Association of preoperative and postoperative serum carcinoembryonic antigen and colon cancer outcome. JAMA Oncol. 2018;4(3):309–15. DOI: 10.1001/jamaoncol.2017.4420</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Lin Y.H., Wu C.H., Fu H.C., Chen Y.J., Chen Y.Y., Ou Y.C., et al. Prognostic significance of elevated pretreatment serum levels of CEA and CA-125 in epithelial ovarian cancer. Cancer Biomark. 2020;28(3):285–92. DOI: 10.3233/CBM-201455</mixed-citation><mixed-citation xml:lang="en">Lin Y.H., Wu C.H., Fu H.C., Chen Y.J., Chen Y.Y., Ou Y.C., et al. Prognostic significance of elevated pretreatment serum levels of CEA and CA-125 in epithelial ovarian cancer. Cancer Biomark. 2020;28(3):285–92. DOI: 10.3233/CBM-201455</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Molina R., Filella X., Lejarcegui J.A., Pahisa J., Torné A., Rovirosa A., et al. Prospective evaluation of squamous cell carcinoma and carcinoembryonic antigen as prognostic factors in patients with cervical cancer. Tumour Biol. 2003;24(3):156–64. DOI: 10.1159/000073846</mixed-citation><mixed-citation xml:lang="en">Molina R., Filella X., Lejarcegui J.A., Pahisa J., Torné A., Rovirosa A., et al. Prospective evaluation of squamous cell carcinoma and carcinoembryonic antigen as prognostic factors in patients with cervical cancer. Tumour Biol. 2003;24(3):156–64. DOI: 10.1159/000073846</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Huang G., Chen R., Lu N., Chen Q., Lv W., Li B. Combined Evaluation of Preoperative Serum CEA and CA125 as an independent prognostic biomarker in patients with early-stage cervical adenocarcinoma. Onco Targets Ther. 2020;13:5155–64. DOI: 10.2147/OTT.S250614</mixed-citation><mixed-citation xml:lang="en">Huang G., Chen R., Lu N., Chen Q., Lv W., Li B. Combined Evaluation of Preoperative Serum CEA and CA125 as an independent prognostic biomarker in patients with early-stage cervical adenocarcinoma. Onco Targets Ther. 2020;13:5155–64. DOI: 10.2147/OTT.S250614</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Campbell J.D., Yau C., Bowlby R., Liu Y., Brennan K., Fan H., et al. Genomic, pathway network, and immunologic features distinguishing squamous carcinomas. Cell Rep. 2018;23(1):194–212.e6. DOI: 10.1016/j.celrep.2018.03.063</mixed-citation><mixed-citation xml:lang="en">Campbell J.D., Yau C., Bowlby R., Liu Y., Brennan K., Fan H., et al. Genomic, pathway network, and immunologic features distinguishing squamous carcinomas. Cell Rep. 2018;23(1):194–212.e6. DOI: 10.1016/j.celrep.2018.03.063</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Gadducci A., Guerrieri M.E., Greco C. Tissue biomarkers as prognostic variables of cervical cancer. Crit Rev Oncol Hematol. 2013;86(2):104–29. DOI: 10.1016/j.critrevonc.2012.09.003</mixed-citation><mixed-citation xml:lang="en">Gadducci A., Guerrieri M.E., Greco C. Tissue biomarkers as prognostic variables of cervical cancer. Crit Rev Oncol Hematol. 2013;86(2):104– 29. DOI: 10.1016/j.critrevonc.2012.09.003</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Xie R., Yang Y., Zhang H., Liu H., Guo J., Qin H., et al. c-Myb and its Effector COX-2 as an indicator associated with prognosis and therapeutic outcome in colorectal cancer. J Cancer. 2019;10(7):1601–10. DOI: 10.7150/jca.27261</mixed-citation><mixed-citation xml:lang="en">Xie R., Yang Y., Zhang H., Liu H., Guo J., Qin H., et al. c-Myb and its Effector COX-2 as an indicator associated with prognosis and therapeutic outcome in colorectal cancer. J Cancer. 2019;10(7):1601–10. DOI: 10.7150/jca.27261</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Karageorgopoulou S., Kostakis I.D., Gazouli M., Markaki S., Papadimitriou M., Bournakis E., et al. Prognostic and predictive factors in patients with metastatic or recurrent cervical cancer treated with platinum- based chemotherapy. Clinical Trial BMC Cancer. 2017;17(1):451. DOI: 10.1186/s12885-017-3435-x</mixed-citation><mixed-citation xml:lang="en">Karageorgopoulou S., Kostakis I.D., Gazouli M., Markaki S., Papadimitriou M., Bournakis E., et al. Prognostic and predictive factors in patients with metastatic or recurrent cervical cancer treated with platinum- based chemotherapy. Clinical Trial BMC Cancer. 2017;17(1):451. DOI: 10.1186/s12885-017-3435-x</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Li W., Ma H., Zhang J., Zhu L., Wang C., Yang Y. Unraveling the roles of CD44/CD24 and ALDH1 as cancer stem cell markers in tumorigenesis and metastasis. Sci Rep. 2017;7(1):13856. DOI: 10.1038/s41598-017-14364-2</mixed-citation><mixed-citation xml:lang="en">Li W., Ma H., Zhang J., Zhu L., Wang C., Yang Y. Unraveling the roles of CD44/CD24 and ALDH1 as cancer stem cell markers in tumorigenesis and metastasis. Sci Rep. 2017;7(1):13856. DOI: 10.1038/s41598-017-14364-2</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Fu Z., Zhang P., Luo H., Huang H., Wang F. CXCL12 modulates the radiosensitivity of cervical cancer by regulating CD44. Mol Med Rep. 2018;18(6):5101–8. DOI: 10.3892/mmr.2018.9554</mixed-citation><mixed-citation xml:lang="en">Fu Z., Zhang P., Luo H., Huang H., Wang F. CXCL12 modulates the radiosensitivity of cervical cancer by regulating CD44. Mol Med Rep. 2018;18(6):5101–8. DOI: 10.3892/mmr.2018.9554</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Dasari S., Rajendra W., Valluru L. Evaluation of soluble CD44 protein marker to distinguish the premalignant and malignant carcinoma cases in cervical cancer patients. Med Oncol. 2014;31(9):139. DOI: 10.1007/s12032-014-0139-9</mixed-citation><mixed-citation xml:lang="en">Dasari S., Rajendra W., Valluru L. Evaluation of soluble CD44 protein marker to distinguish the premalignant and malignant carcinoma cases in cervical cancer patients. Med Oncol. 2014;31(9):139. DOI: 10.1007/s12032-014-0139-9</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Sidorkiewicz I., Piskór B., Dąbrowska E., Guzińska-Ustymowicz K., Pryczynicz A., Zbucka-Krętowska M., et al. Plasma levels and tissue expression of selected cytokines, metalloproteinases and tissue inhibitors in patients with cervical cancer. Anticancer Res. 2019;39(11):6403–12. DOI: 10.21873/anticanres.13854</mixed-citation><mixed-citation xml:lang="en">Sidorkiewicz I., Piskór B., Dąbrowska E., Guzińska-Ustymowicz K., Pryczynicz A., Zbucka-Krętowska M., et al. Plasma levels and tissue expression of selected cytokines, metalloproteinases and tissue inhibitors in patients with cervical cancer. Anticancer Res. 2019;39(11):6403–12. DOI: 10.21873/anticanres.13854</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Li Y., Wu T., Zhang B., Yao Y., Yin G. Matrix metalloproteinase-9 is a prognostic marker for patients with cervical cancer. Med Oncol. 2012;29(5):3394–9. DOI: 10.1007/s12032-012-0283-z</mixed-citation><mixed-citation xml:lang="en">Li Y., Wu T., Zhang B., Yao Y., Yin G. Matrix metalloproteinase-9 is a prognostic marker for patients with cervical cancer. Med Oncol. 2012;29(5):3394–9. DOI: 10.1007/s12032-012-0283-z</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Roslind A., Palle C., Johansen J.S., Christensen I.J., Nielsen H.J., Mosgaard B.J. Prognostic utility of serum YKL-40 in patients with cervical cancer. Scand J Clin Lab Invest. 2020;80(8):687–93. DOI: 10.1080/00365513.2020.1846209</mixed-citation><mixed-citation xml:lang="en">Roslind A., Palle C., Johansen J.S., Christensen I.J., Nielsen H.J., Mosgaard B.J. Prognostic utility of serum YKL-40 in patients with cervical cancer. Scand J Clin Lab Invest. 2020;80(8):687–93. DOI: 10.1080/00365513.2020.1846209</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Anggraeni T.D., Rustamadji P., Aziz M.F. Fas Ligand (FasL) in Association with Tumor-Infiltrating Lymphocytes (TILs) in early stage cervical cancer. Asian Pac J Cancer Prev. 2020;21(3):831–5. DOI: 10.31557/APJCP.2020.21.3.831</mixed-citation><mixed-citation xml:lang="en">Anggraeni T.D., Rustamadji P., Aziz M.F. Fas Ligand (FasL) in Association with Tumor-Infiltrating Lymphocytes (TILs) in early stage cervical cancer. Asian Pac J Cancer Prev. 2020;21(3):831–5. DOI: 10.31557/APJCP.2020.21.3.831</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
